DOT1L methyltransferase inhibition has also been explored in MLL-rearranged leukemias which are highly dependent on abnormal DOT1L H3K79 methylation, indicating DOT1L inhibitors as potential therapeutic agents (Figure 4) [154]. This evidence concerns the gene KMT2A and leukemia.